FDA probes new pancreas risks with diabetes drugs - New York News

FDA probes new pancreas risks with diabetes drugs

Posted: Updated:

By MATTHEW PERRONE, AP Health Writer

WASHINGTON (AP) — The Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.

The agency said Thursday samples of pancreas tissue taken from a small number of patients showed inflammation and cellular changes that often precede cancer. Academic researchers took the samples from diabetes patients who were taking the new medications, after they died from various causes.

Details of the research have not yet been published, but the agency said in an online statement it is seeking more information.

While the FDA has issued previous alerts about the pancreatitis risk, the agency had not notified the public about pre-cancerous cell changes seen with the drugs.

For now, regulators say they are still investigating the issue.

"FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer," the agency said in an online statement. "At this time, patients should continue to take their medicine as directed until they talk to their health care professional."

The drugs under review come from a wave of recently approved diabetes medications, including Merck's Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon, among others. All the drugs mimic natural hormones that the body usually produces to spur insulin production after a meal.

Citi Investment Research analyst Andrew Baum told investors the investigation would likely have "minimal impact" on drug sales.  Similar investigations in recent years have not resulted in safety restrictions, he says.

"We believe that the likely worst case for the market incumbents is that the FDA could add additional warnings about increased risk of pancreas-related adverse events" Baum stated in a research note.

People with type 2 diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Many diabetics require multiple drugs with different mechanisms of action to control their blood sugar levels.

With more than 25 million people living with diabetes in the U.S., some of the world's biggest drugmakers have launched new treatments in recent years, though safety questions have emerged.

The FDA previously added information about cases of pancreatitis, some of them fatal, to the labels of Byetta in 2007, and Januvia and Janumet in 2009.

A recent study of insurance records found that use of those drugs could double the risk of developing acute pancreatitis, according to the FDA.

Januvia is a once-a-day pill. Janumet combines the drug with metformin, a decades-old drug commonly prescribed for diabetes. Byetta is a twice-a-day injection originally developed by Amylin Pharmaceuticals. Bristol-Myers acquired the drug last year, along with the newer formulation Bydureon, which is taken once-a-week.

Byetta and Bydureon are part of a drug class that mimics the GLP-1 hormone, triggering insulin production after a meal.

Januvia and Janumet work by blocking the DPP-4 enzyme, which spurs release of more insulin from the pancreas. Those drugs brought in a total of about $5.75 billion last year, making them Merck's biggest franchise.

The pancreas produces various hormones, including insulin, that help the body break down sugar. Pancreatitis causes an inflammation of the organ and can lead to fatal complications, including difficulty breathing and kidney failure.

Shares of Whitehouse Station, N.J.-based Merck & Co. Inc. fell 32 cents to $44.27. Shares of New York-based Bristol-Myers Squibb Co. declined 1 cent to $38.48.

AP Business Writer Linda A. Johnson contributed to this story from Trenton, N.J.

--- 

A look at the diabetes drugs under investigation by the U.S.  Food and Drug Administration over possible risks of pancreas inflammation and cellular changes in the pancreas that occur before cancer.

DRUG CLASS: GLP-1 mimickers, taken by nearly 1 million Americans.

HOW THEY WORK: Injections needed anywhere from twice a day to once a week, they make the body produce more insulin to lower blood sugar.

MAKER: Bristol-Myers Squibb Co.

CHEMICAL/BRAND NAMES: exenatide/Byetta and Bydureon

MAKER: Novo Nordisk A/S:

CHEMICAL/BRAND NAMES: liraglutide/Victoza

___

DRUG CLASS: DPP-4 inhibitors, taken by about 1.6 million Americans.

HOW THEY WORK: Pills taken once or twice a day, they stimulate insulin production and limit release of a hormone that raises blood sugar levels.

MAKER: Merck & Co.

CHEMICAL/BRAND NAMES: sitagliptin/Januvia, Janumet, Janumet XR, Juvisync

MAKER: Bristol-Myers Squibb Co. & AstraZeneca PLC

CHEMICAL/BRAND NAMES:  saxagliptin/Onglyza and Kombiglyze

MAKER: Eli Lilly and Co. and  Boehringer Ingelheim Pharmaceuticals Inc.

CHEMICAL/BRAND NAMES: linagliptin/Jentadueto and Tradjenta

MAKER: Takeda Pharmaceuticals Co. Ltd.

CHEMICAL/BRAND NAMES: alogliptin/Nesina, Kazano and Oseni

___

Source: Company websites, health data firm Kantar Health.

Copyright 2013 The Associated Press.

  • HealthMore>>

  • Teen caught urinating in reservoir

    Teen caught urinating in reservoir

    Thursday, April 17 2014 8:24 AM EDT2014-04-17 12:24:39 GMT
    Once again, Portland officials are preparing to flush millions of gallons of treated water because a young person urinated into a city reservoir.  Water Bureau Administrator David Shaff said 38 million gallons will be discarded because a 19-year-old was caught in the act on Wednesday.
    Once again, Portland officials are preparing to flush millions of gallons of treated water because a young person urinated into a city reservoir.  Water Bureau Administrator David Shaff said 38 million gallons will be discarded because a 19-year-old was caught in the act on Wednesday.
  • Allergy season expected to be bad

    Allergy season expected to be bad

    Wednesday, April 16 2014 6:56 AM EDT2014-04-16 10:56:12 GMT
    There is not much relief in sight for allergy sufferers. Experts say a shortened spring due to the long winter may create a more intense allergy season.  Some allergists say they've already seen a noticeable increase in patients as the weather has gotten warmer.
    There is not much relief in sight for allergy sufferers. Experts say a shortened spring due to the long winter may create a more intense allergy season.  Some allergists say they've already seen a noticeable increase in patients as the weather has gotten warmer.
  • FDA's warning letter to maker of controversial supplement Craze

    FDA's warning letter to maker of controversial supplement Craze

    Tuesday, April 15 2014 10:38 PM EDT2014-04-16 02:38:33 GMT
    A report first surfaced last year about meth-like substances in Craze. The product was immediately pulled from the shelves of many major retailers, including Walmart. Now the federal government is taking its first action against the company behind the product. The supplement Craze was marketed as a product offering endless energy, a preworkout supplement popular with body builders. But a warning letter from the FDA confirms what Harvard scientists have previously alleged.
    A report first surfaced last year about meth-like substances in Craze. The product was immediately pulled from the shelves of many major retailers, including Walmart. Now the federal government is taking its first action against the company behind the product. The supplement Craze was marketed as a product offering endless energy, a preworkout supplement popular with body builders. But a warning letter from the FDA confirms what Harvard scientists have previously alleged.
  • Local NewsLocal NewsMore>>

  • Rifle seized after squirrel shooting in Milford

    Rifle seized after squirrel shooting in Milford

    Thursday, April 17 2014 8:48 AM EDT2014-04-17 12:48:12 GMT
    Connecticut State NewsConnecticut State News
    Police say they found an unregistered assault rifle and three large-capacity magazines in the home of a Milford man accused of shooting a squirrel.  James Toigo has been charged with unlawful discharge of a firearm, cruelty to an animal, reckless endangerment, breach of peace, failure to register an assault rifle and possessing large-capacity magazines.
    Police say they found an unregistered assault rifle and three large-capacity magazines in the home of a Milford man accused of shooting a squirrel.  James Toigo has been charged with unlawful discharge of a firearm, cruelty to an animal, reckless endangerment, breach of peace, failure to register an assault rifle and possessing large-capacity magazines.
  • Harlem politician Basil Paterson dead

    Harlem politician Basil Paterson dead

    Thursday, April 17 2014 8:41 AM EDT2014-04-17 12:41:03 GMT
    Basil Paterson, the father of former New York Governor David Paterson, died Wednesday night at the age of 87. The trailblazing Democratic politician from Harlem served in the state Senate, as deputy mayor of New York City, as secretary of state of New York and was appointed by the New York Senate as a commissioner of the Port Authority of NY and NJ. In 1970, he ran for lieutenant governor, the second black nominee of a major party for statewide office in New York.
    Basil Paterson, the father of former New York Governor David Paterson, died Wednesday night at the age of 87. The trailblazing Democratic politician from Harlem served in the state Senate, as deputy mayor of New York City, as secretary of state of New York and was appointed by the New York Senate as a commissioner of the Port Authority of NY and NJ. In 1970, he ran for lieutenant governor, the second black nominee of a major party for statewide office in New York.
  • Fund raises thousands for exonerated NYC man

    Fund raises thousands for exonerated NYC man

    Thursday, April 17 2014 8:20 AM EDT2014-04-17 12:20:44 GMT
    A recently exonerated New York man who spent nearly 25 years behind bars for a killing that happened while he was at Disney World is getting help from dozens of well-wishers contributing to an online fund for him. About 70 people gave a total of more than $3,400 to the campaign for Jonathan Fleming by Wednesday. Fleming was released last week after a judge dismissed the 1989 case, with Brooklyn prosecutors' assent.
    A recently exonerated New York man who spent nearly 25 years behind bars for a killing that happened while he was at Disney World is getting help from dozens of well-wishers contributing to an online fund for him. About 70 people gave a total of more than $3,400 to the campaign for Jonathan Fleming by Wednesday. Fleming was released last week after a judge dismissed the 1989 case, with Brooklyn prosecutors' assent.
Powered by WorldNow
Didn't find what you were looking for?
All content © Copyright 2000 - 2014 Fox Television Stations, Inc. and Worldnow. All Rights Reserved.
Privacy Policy | Terms of Service | Ad Choices